Figure 1.
Comparison of gemcitabine chemosensitization by either MK8776 or AZD1775 in pancreatic cancer cells. Cells treated with equitoxic concentrations of gemcitabine from t0 – t2 (250 nM, MiaPaCa-2, BxPC3 and Panc1; 500 nM, AsPC1 or 50 nM, Capan1) and either MK8776 or AZD1775 from t24 – t48 as illustrated (A) were assayed for clonogenic survival (B-E). Data presented are the mean ± SEM of n = 2–6 independent experiments and are normalized to the plating efficiency of cells treated with inhibitor alone. The minimum concentrations of either MK8776* or AZD1775δ required to produce statistically significant gemcitabine chemosensitization are indicated (P < 0.05, one-way ANOVA).